The Cholangiocarcinoma Foundation is partnering with Komodo Health to combine information, data, and disease-treatment reference points through Komodo’s largest, most-actionable healthcare map in the U.S.
This first-of-its-kind agreement will enable the foundation to have a nearly real-time and comprehensive picture of the patient landscape. With this information, the foundation is now able to provide patients with timely information on local specialists and give local providers data on promising cancer therapies.
“The partnership we have forged with Komodo Health is truly groundbreaking,” said Cholangiocarcinoma Foundation President and Founder Stacie Lindsey. “For the first time, we will have access to critical information that will allow us to impact the speed and quality of care for our patients and to objectively identify centers offering the most promising therapies and clinical trials.”
Cholangiocarcinoma is a “silent” form of cancer that originates from the cells lining the bile ducts. Approximately 9,000 new cases are diagnosed each year, and the disease now has the second-highest rising incidence rate.
The partnership between Komodo Health and the Cholangiocarcinoma Foundation will accelerate access to the best possible care; establish accurate measurements on cholangiocarcinoma epidemiology, and help set a higher standard of care for how cholangiocarcinoma patients are treated.
It will also provide other benefits for the foundation, including the ability to use anonymized patient data to see where cholangiocarcinoma patients are being treated in order to guide education and outreach efforts, and identify and more effectively partner with biopharma companies that are in early-phase development of treatments.
Komodo Health, a McKesson Ventures portfolio company, curates proprietary healthcare databases to facilitate data-driven discovery, segmentation and analysis, cross-functional workflow and intelligence sharing, and tracking/reporting.
Read the full press release here.